

AGE

CONNECT
mu

READER

Know their risk.

Non-invasive cardiovascular risk assessment


The AGE Reader provides an immediate prediction for the cardiovascular risk of your patient. The non-invasive and extensively validated AGE Reader is an ideal tool for point of care testing. The measurement result is available in 12 seconds and can be exported directly.



About AGEs

(Advanced Glycation Endproducts)

AGEs are the result of a chain of chemical reactions (the Maillard reaction) after an initial glycation. AGEs normally accumulate slowly over a person's lifetime in tissues with slow turnover. But this process occurs more rapidly in patients with conditions such as diabetes mellitus, renal failure and cardiovascular disease. AGEs also accumulate rapidly under circumstances of oxidative stress. These accumulated AGEs play a key role in the development of diabetes and its complications. The level of AGEs in tissue reflects the glycometabolic memory and is a valuable predictor of cardiovascular events and (pre)diabetes.



AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure.

Measuring AGEs

With any other measurement it has been complicated to measure tissue AGEs in patients because they are expensive, time consuming, lack specificity, are poorly reproducible and/or are invasive. The AGE Reader is the answer to the need for measuring AGEs without the disadvantages of the existing methods. This state of the art device provides a simple non-invasive solution, which allows clinicians to determine the AGE level within 12 seconds.

Many advanced glycation endproducts (AGEs) have a characteristic fluorescence. Moreover, tissue fluorescence in (invasive) biopsies has an established association with chronic complications. The AGE Reader is able to easily, quickly and noninvasively measure AGEs by means of fluorescence techniques¹.




AGE Reader

The AGE Reader provides an immediate prediction for cardiovascular risk. The measurement is reliable, real time, non-invasive and easy to use.

Moreover, the AGE Reader has been validated in clinical studies around the world. The AGE Reader has been used in clinical practice and research since 2006 in over 1000 clinics worldwide. Since the introduction of the AGE Reader more than 200 peer reviewed papers have been published. These papers give an overview of clinical studies in diabetes², cardiovascular disease³ and renal disease⁴.



Type 2 Diabetes population (n=987)



Clinical validation

Key conclusions of the clinical validation studies using the AGE Reader:

- Reflects vascular damage in the diabetes patients².
- Identifies diabetic patients at risk of developing (cardiovascular and microvascular) complications^{5,6,7}.
- Predicts the risk of having or developing diabetes and the metabolic syndrome^{8,9}.
- Strong predictor of major cardiovascular events in peripheral artery disease¹⁰.

Clinical use

Clinical professionals have been successfully using the AGE Reader in their clinics for over 10 years. The AGE Reader is the answer to the need to quickly, reliably and non-invasively measure the cardiovascular risk of your patient.



The AGE Reader assists clinical professionals in identifying patients with an increased cardiovascular risk. This helps clinicians to decide whether a change in treatment is needed.

This non-invasive and convenient measurement can be performed by any clinical professional and is completed within 12 seconds.

The AGE Reader App

Export the measurement directly to the AGE Reader App using the Bluetooth connection and add other cardiovascular risk factors to generate a comprehensive Cardiovascular Risk Report. For each patient all visits can be documented and consulted in the easy to use App. The Cardiovascular Risk Report can simply be **printed, saved and shared**.

Download the AGE Reader App free of charge on www.diagnoptics.com. Available for:



Explain & Motivate patients

The graphical display allows you to combine the AGE Reader result with desired other cardiovascular risk factors and explain the results to patients. A hardcopy of the report can be handed to the patient, which will make it easier to understand the measurement result and the associated cardiovascular risk.

References

1. Meerwaldt R. et al. Diabetologia. 2004; 47(7): 1324-1330.
2. Lutgers H. et al. Diabetes Care. 2006; 29(12): 2654-2659.
3. Hofmann B. et al. Exp Gerontol. 2012 Epub May 12.
4. McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Oct;6(10):2356-63.
5. Lutgers H. et al. Diabetologia, 2009; 52(5): 789-797.
6. Gerrits E. et al. Diabetes care. 2008; 31(3): 517-521.
7. Noordzij M. et. Diabet Med. 2012; 29(12): 1556-1561.
8. Van Waateringe et al. Diabetol Metab Syndr. 2017 May 30;9:42
9. Oral and poster presentations EASD 2017. Submitted for publication
10. De vos L. et al. Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):933-8

Please visit www.diagnoptics.com/age-reader for a complete overview of all AGE Reader publications.



Diagnostics Technologies B.V.

www.diagnoptics.com

www.age-reader.com



錫昌科技股份有限公司
KYS Technology

T 02-2911-5233 F 02-2911-6855 E info@kyst.com.tw www.kyst.com.tw